Pharmacokinetics of ofloxacin, a fluoroquinolone antimicrobial agent, was determined in broiler chickens after intravenous or oral administration of a single dose (10 mg/kg). Ofloxacin concentrations in plasma were determined using a high-performance liquid chromatography assay. Plasma concentration profiles were analyzed by the noncompartmental method. Elimination half-life and mean residence time of ofloxacin in plasma were 4.46 and 5.48 h after intravenous administration and 5.85 and 7.43 h, respectively, after oral administration. Maximal plasma concentration of 3.65 microg/mL was achieved at 1.25 h after oral administration. Apparent volume of distribution of 1.76 and 2.16 L/kg and total body clearance of 4.96 and 4.5 mL/min/kg were obtained following intravenous and oral administration, respectively. The oral bioavailability of ofloxacin was 110.01%. Ofloxacin was found to be more rapidly absorbed, widely distributed and more quickly eliminated than other fluoroquinolones in broilers. Based on these kinetic parameters, a dosage of 10 mg/kg given orally every 24 h can be recommended for the treatment of bacterial infections with MIC90 < 0.3 microg/mL.

The anti-inflammatory effect of a petroleum ether extract of Vitex negundo Linn (Verbenaceae) leaves, (PEVNL) (250 and 500 mg/kg, p.o.), was evaluated in carrageenan-induced hind paw edema and cotton pellet granuloma models. Diclofenac sodium was used as a standard drug. The biochemical parameters were estimated in serum. In carrageenan-induced rat paw edema model PEVNL exhibited significant (p < 0.01) inhibition of edema volume at 4 h in a dose-dependent manner. In the cotton pellet granuloma model, dry weight of cotton pellets was significantly inhibited in a dose-dependent manner with maximum effect noticed at 500 mg/kg, p.o. Both doses of PEVNL were found to normalize the increased alkaline phosphatase, acid phosphatase, alanine amino transferase (ALT) and aspartate amino transferase (AST) and reversed the decreased serum albumin. In conclusion, PEVNL exhibited anti-inflammatory activity in acute and subacute models. At a dose of 500 mg/kg, p.o., PEVNL was found to possess maximum activity, and this effect was comparable with reference drug diclofenac sodium (5 mg/kg, p.o.).

1. The pharmacokinetics of sparfloxacin in broiler chicken was investigated following a single intravenous dose of 10 mg/kg and a single oral dose of 20 mg/kg. The pharmacokinetic parameters (AUC(0-24) or C(max)) were integrated with the pharmacodynamic parameter (MIC(90)) to optimize sparfloxacin dosage in chicken. 2. The apparent volume of distribution, total body clearance, mean residence time and elimination half-life following oral administration were 2.411/kg, 4.55 ml/min per kg, 10.54 and 5.94 h, respectively. Oral bioavailability was 61.7%. 3. Sparfloxacin was found to possess clinically useful pharmacokinetic properties. Based on pharmacokinetic/pharmacodynamic integration an oral dose of 20 mg/kg sparfloxacin for every 24 h might be recommended for a successful clinical effect in chickens.